Ryan N. Cole
YOU?
Author Swipe
View article: Androgen receptor inhibitors in treating prostate cancer
Androgen receptor inhibitors in treating prostate cancer Open
Androgens play an important role in prostate cancer development and progression. Androgen action is mediated through the androgen receptor (AR), a ligand-dependent DNA-binding transcription factor. AR is arguably the most important target …
View article: Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Identification of novel androgen receptor (AR) antagonists may lead to urgently needed new treatments for patients with prostate cancer resistant to current AR antagonists. AR is presently the main target for treating prostate cancer. Clin…
View article: Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Identification of novel androgen receptor (AR) antagonists may lead to urgently needed new treatments for patients with prostate cancer resistant to current AR antagonists. AR is presently the main target for treating prostate cancer. Clin…
View article: Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer.
Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer. Open
The androgen receptor (AR) remains to be a key target for the treatment of prostate cancer, including the majority of castration-resistant prostate cancer (CRPC). AR is stabilized in CRPC and the ubiquitin-proteasome system (UPS) plays a m…
View article: The classical and updated models of androgen receptor nucleocytoplasmic trafficking.
The classical and updated models of androgen receptor nucleocytoplasmic trafficking. Open
This mini-review covers the classical model of androgen receptor (AR) nucleocytoplasmic trafficking and provides an overview of new data that updates the existing paradigm. The classical model of androgen receptor trafficking involves AR t…
View article: Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer Open
Nuclear localization of the androgen receptor (AR) is necessary for its activation as a transcription factor. Defining the mechanisms regulating AR nuclear localization in androgen-sensitive cells and how these mechanisms are dysregulated …